The research, sponsored by the company, provides a physician-reported assessment of how the injectable medication is currently utilized in complex, treatment-refractory cases. By analyzing real-world data, the manuscript offers insights into patient characteristics and the practical application of the therapy across three distinct autoimmune conditions.

George J. Wan, senior author of the study and Vice President at Keenova, noted that real-world evidence for the drug in these specific therapeutic areas has historically been limited. The findings aim to assist clinicians in navigating treatment options for patients who have not responded to prior therapies. According to Dr. Marek Honczarenko, Chief Scientific Officer at Keenova, the company remains focused on advancing the clinical data behind the therapy to support its use as an option for eligible patients.